A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections. (August 2015)

• Record Type: Journal Article
• Authors: Chan, Cynthia; Hardin, Thomas C; Smart, Jennifer I
• Is Part Of: Future microbiology. Volume 10:Number 8(2015:Aug.)
• Page Start: 1325
• Page End: 1338
• Publication Date: 2015-08
• Subjects: biofilm -- device-associated infections -- endocarditis -- osteomyelitis -- telavancin; Microbiology -- Research -- Periodicals; 616.9041
• DOI: 10.2217/fmb.15.53
• Languages: English
• ISSNs: 1746-0913

Abstract

ABSTRACT : Tissue- and device-associated biofilm infections are important medical problems. These infections are difficult to treat due to a high-level of tolerance to antibiotics. Telavancin has been studied in several in vitro biofilm models and has demonstrated efficacy against staphylococcal and enterococcal-associated biofilm infections, including those formed by methicillin-resistant Staphylococcus aureus . Telavancin was effective against the difficult-to-treat vancomycin- and glycopeptide-intermediate strains of S. aureus in these models. Furthermore, the efficacy of telavancin has been evaluated in several biofilm-related in vivo models, including osteomyelitis, endocarditis and device-associated infections in rabbits. Overall, telavancin exhibited similar or greater efficacy than vancomycin and other comparators in these animal models and maintained activity against vancomycin-intermediate and daptomycin nonsusceptible strains of S. aureus .